Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anamorelin in Advanced Cancer with Cancer-Related Fatigue
NCT03035409Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Feb 2017
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of anamorelin in cancer-related fatigue (CRF), sponsored by University of Texas MD Anderson Cancer Center. Started Feb 2017; status: active, not recruiting.
02
Drugs
anamorelin
03
Conditions
cancer-related fatigue (CRF)
Beyond the preview
Go deeper on NCT03035409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03035409.